1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Epiomic Epidemiology Series: Restless Leg Syndrome Forecast in 13 Major Markets 2016-2026

Epiomic Epidemiology Series: Restless Leg Syndrome Forecast in 13 Major Markets 2016-2026

  • February 2016
  • -
  • Black Swan Analysis Ltd
  • -
  • 52 pages

Summary

Table of Contents

Search Inside

Summary

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Restless Legs Syndrome in 13 Major Markets

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disorder, is a sensimotor sleep disorder. Clinically, RLS is characterized by disagreeable leg sensations occurring most often at sleep onset that provoke an irresistible urge to move legs. Patients with RLS typically complain of itching, creeping and tingling in their legs, usually between the ankle and the knee. The unpleasant sensations occur when the individual is at rest and are more pronounced in the evening or at night. The unpleasant sensations are relieved temporarily with leg movements.

This report provides the current prevalent population for Restless Legs Syndrome across 13 Major Markets (USA, France, Germany, Italy, Spain, UK, Turkey, Brazil, Mexico, Republic of Korea, India, China and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Restless Legs Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Restless Legs Syndrome include:

-Insomnia
-Depression
-Periodic Limb Movements
-Panic Disorder

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reasons to buy
-Able to quantify patient populations in global Restless Legs Syndrome’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of Restless Legs Syndrome and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Restless Legs Syndrome’s prevalent population.
-Identify sub-populations within Restless Legs Syndrome which require treatment.
-Gain an understanding of the specific markets that have the largest number of Restless Legs Syndrome patients.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.